Pharmaceutical companies could slash their pharmacovigilance costs by half while significantly improving accuracy through generative AI, according to IQVIA’s Global Practice Lead of Pharmacovigilance Technologies, Uwe Trinks. “The idea is: we can save 50% of the cost and get the quality to above 99%,” Trinks said. “That means when we have human verification, we only…
![[Adobe Stock]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/11/AdobeStock_844651123-copy-268x170.webp)